{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:39:43Z","timestamp":1790008783993,"version":"4.0.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/gme.0b013e3181e102eb","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T03:44:24Z","timestamp":1278474264000},"page":"1122-1127","source":"Crossref","is-referenced-by-count":57,"title":["Activated protein C resistance among postmenopausal women using transdermal estrogens"],"prefix":"10.1097","volume":"17","author":[{"given":"Marianne","family":"Canonico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Alhenc-Gelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Plu-Bureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Oli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Scarabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210227","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R2-9-20210227","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"R3-9-20210227","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.","volume":"336","author":"Canonico","year":"2008","journal-title":"BMJ"},{"key":"R4-9-20210227","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"key":"R5-9-20210227","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"R6-9-20210227","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/ATVBAHA.109.196022","article-title":"Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.","volume":"30","author":"Canonico","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R7-9-20210227","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/369064a0","article-title":"Mutation in blood coagulation factor V associated with resistance to activated protein C.","volume":"369","author":"Bertina","year":"1994","journal-title":"Nature"},{"key":"R8-9-20210227","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","article-title":"A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.","volume":"93","author":"de Visser","year":"1999","journal-title":"Blood"},{"key":"R9-9-20210227","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1161\/01.ATV.17.11.3071","article-title":"Effects of oral and transdermal estrogen\/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.","volume":"17","author":"Scarabin","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R10-9-20210227","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/01.ATV.0000087141.05044.1F","article-title":"Differential effects of oral and transdermal estrogen\/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial.","volume":"23","author":"Oger","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R11-9-20210227","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/01.ATV.0000074146.36646.C8","article-title":"Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.","volume":"23","author":"Post","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R12-9-20210227","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma.","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"R13-9-20210227","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/s-0037-1614514","article-title":"Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes.","volume":"81","author":"Alhenc-Gelas","year":"1999","journal-title":"Thromb Haemost"},{"key":"R14-9-20210227","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/bmj.39266.425069.AD","article-title":"Main morbidities recorded in the Women's International Study of Long Duration Oestrogen After Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.","volume":"335","author":"Vickers","year":"2007","journal-title":"BMJ"},{"key":"R15-9-20210227","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis.","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"key":"R16-9-20210227","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinte.166.7.772","article-title":"Venous thrombosis and conjugated equine estrogen in women without a uterus.","volume":"166","author":"Curb","year":"2006","journal-title":"Arch Intern Med"},{"key":"R17-9-20210227","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2003.04443.x","article-title":"Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.","volume":"122","author":"Tans","year":"2003","journal-title":"Br J Haematol"},{"key":"R18-9-20210227","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1055\/s-0037-1616085","article-title":"Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein-a cross-sectional population survey.","volume":"86","author":"Lowe","year":"2001","journal-title":"Thromb Haemost"},{"key":"R19-9-20210227","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1055\/s-0037-1615643","article-title":"Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.","volume":"85","author":"Vehkavaara","year":"2001","journal-title":"Thromb Haemost"},{"key":"R20-9-20210227","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0021-9150(03)00088-1","article-title":"Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis.","volume":"168","author":"Zegura","year":"2003","journal-title":"Atherosclerosis"},{"key":"R21-9-20210227","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.maturitas.2004.03.011","article-title":"Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women.","volume":"50","author":"Martinez","year":"2005","journal-title":"Maturitas"},{"key":"R22-9-20210227","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.maturitas.2005.02.024","article-title":"Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women.","volume":"52","author":"Callejon","year":"2005","journal-title":"Maturitas"},{"key":"R23-9-20210227","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000211676","article-title":"Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.","volume":"68","author":"Perrone","year":"2009","journal-title":"Gynecol Obstet Invest"},{"key":"R24-9-20210227","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1590\/S1807-59322007000500004","article-title":"Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women.","volume":"62","author":"Bonduki","year":"2007","journal-title":"Clinics (Sao Paulo)"},{"key":"R25-9-20210227","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2141.2004.04846.x","article-title":"Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers.","volume":"124","author":"Stevenson","year":"2004","journal-title":"Br J Haematol"},{"key":"R26-9-20210227","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1160\/TH06-10-0567","article-title":"Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?","volume":"97","author":"Brosnan","year":"2007","journal-title":"Thromb Haemost"},{"key":"R27-9-20210227","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1161\/01.ATV.0000224325.96659.53","article-title":"Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.","volume":"26","author":"Hemelaar","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R28-9-20210227","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0015-0282(16)57909-6","article-title":"Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol.","volume":"64","author":"Conard","year":"1995","journal-title":"Fertil Steril"},{"key":"R29-9-20210227","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0037-1613752","article-title":"Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.","volume":"83","author":"van Baal","year":"2000","journal-title":"Thromb Haemost"},{"key":"R30-9-20210227","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2002.00960.x","article-title":"Oral oestradiol\/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women.","volume":"251","author":"Post","year":"2002","journal-title":"J Intern Med"},{"key":"R31-9-20210227","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1160\/TH07-12-0746","article-title":"Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)\/dydrogesterone and estradiol (2 mg)\/trimegestone.","volume":"100","author":"Norris","year":"2008","journal-title":"Thromb Haemost"},{"key":"R32-9-20210227","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2141.2001.03111.x","article-title":"Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.","volume":"115","author":"Hoibraaten","year":"2001","journal-title":"Br J Haematol"},{"key":"R33-9-20210227","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1055\/s-0037-1616121","article-title":"The effects of transdermal and oral estrogen\/progesterone regimens on free and total protein S in postmenopausal women.","volume":"86","author":"Marque","year":"2001","journal-title":"Thromb Haemost"},{"key":"R34-9-20210227","doi-asserted-by":"crossref","first-page":"17499","DOI":"10.1074\/jbc.271.29.17499","article-title":"The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors.","volume":"271","author":"Regan","year":"1996","journal-title":"J Biol Chem"},{"key":"R35-9-20210227","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1994.291","article-title":"Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.","volume":"70","author":"Plu-Bureau","year":"1994","journal-title":"Br J Cancer"},{"key":"R36-9-20210227","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00002512-200421130-00004","article-title":"New progestogens: a review of their effects in perimenopausal and postmenopausal women.","volume":"21","author":"Sitruk-Ware","year":"2004","journal-title":"Drugs Aging"},{"key":"R37-9-20210227","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130500148875","article-title":"Pharmacology of estrogens and progestogens: influence of different routes of administration.","volume":"8","author":"Kuhl","year":"2005","journal-title":"Climacteric"},{"key":"R38-9-20210227","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1538-7836.2005.01693.x","article-title":"Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism.","volume":"4","author":"Simon","year":"2006","journal-title":"J Thromb Haemost"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/gme.0b013e3181e102eb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:30:08Z","timestamp":1786041008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042192-201017060-00009"}},"subtitle":["importance of progestogen"],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e3181e102eb","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}